| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
Flusilazole (Olymp; DPX-6573; Sanction; Flusilazole; DPX6573; Flusilazol; DPX 6573; Nustar) is a potent organosilicon fungicide that has been used for the control of fungal infections on a variety of vegetable and fruit crops. It shows moderate toxicity to animals and can produce embryotoxicity and birth defects at high doses.
| Toxicity/Toxicokinetics |
Toxicity Summary
Flusilazole dose-dependently inhibits serum testosterone and estradiol concentrations in rats. This inhibition of testosterone and estradiol biosynthesis may disrupt the hypothalamic-pituitary-testicular axis, leading to overstimulation of testicular endocrine tissue and increasing the risk of interstitial cell tumors. Toxicity Data LD50 (rat, oral) = 1110 mg/kg (m²) LD50 (rat, dermal) > 2000 mg/kg |
|---|---|
| References | |
| Additional Infomation |
Flusilazole is an organosilicon compound with the structure dimethylsilane, in which the hydrogen atom bonded to the silicon atom is replaced by a p-fluorophenyl group, and the hydrogen atom bonded to one of the methyl groups is replaced by a 1H-1,2,4-triazol-1-yl group. It is a broad-spectrum fungicide used to protect a variety of crops. It has multiple functions, including acting as an exogenous substance, an environmental pollutant, an EC 1.14.13.70 (sterol 14α-demethylase) inhibitor, and an antifungal pesticide. It belongs to the monofluorobenzene class, triazole class, organosilicon compound, azole fungicide, and triazole fungicide. Flusilazole (DPX-H6573) is an organosilicon fungicide invented by DuPont for controlling fungal infections in various fruit and vegetable crops. It has moderate toxicity to animals, and high doses have been shown to cause birth defects and embryotoxicity.
|
| Molecular Formula |
C16H15F2N3SI
|
|---|---|
| Molecular Weight |
315.39
|
| Exact Mass |
315.1
|
| Elemental Analysis |
C, 60.93; H, 4.79; F, 12.05; N, 13.32; Si, 8.90
|
| CAS # |
85509-19-9
|
| PubChem CID |
73675
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
392.5±52.0 °C at 760 mmHg
|
| Melting Point |
51-53ºC
|
| Flash Point |
191.2±30.7 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.563
|
| LogP |
3.84
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
333
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1C=CC([Si](CN2C=NC=N2)(C)C2C=CC(F)=CC=2)=CC=1
|
| InChi Key |
FQKUGOMFVDPBIZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H15F2N3Si/c1-22(12-21-11-19-10-20-21,15-6-2-13(17)3-7-15)16-8-4-14(18)5-9-16/h2-11H,12H2,1H3
|
| Chemical Name |
1-((bis(4-fluorophenyl)(methyl)silyl)methyl)-1H-1,2,4-triazole
|
| Synonyms |
Nustar; Olymp; Sanction; DPX-6573; DPX6573; DPX 6573;
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~317.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.93 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (7.93 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1707 mL | 15.8534 mL | 31.7068 mL | |
| 5 mM | 0.6341 mL | 3.1707 mL | 6.3414 mL | |
| 10 mM | 0.3171 mL | 1.5853 mL | 3.1707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
